Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human TAK-280 dose-escalation study in advanced unresectable or metastatic cancer
2023-504012-16-00Phase 2Completed
- Sponsor
- Takeda
- Start
- Jan 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of TAK-280 in cancer and metastatic castration-resistant prostate cancer (mCRPC), sponsored by Takeda. Primary endpoints: Number of participants with treatment-emergent adverse events and Number of participants with dose-limiting toxicities. Started Jan 2024; status: completed.
02
Drugs
TAK-280
03
Conditions
cancermetastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2023-504012-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504012-16-00.